Summary of status of development and availability of variant influenza A(H3N2) candidate vaccine viruses (WHO, January 6 2012, edited)

[Giuseppe]

[Source: World Health Organization, full PDF document: (LINK). Edited.]


Summary of status of development and availability of variant influenza A(H3N2) candidate vaccine viruses*


* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System National or Regional control authorities approve the composition and formulation of vaccines used in each country



7 November 2011 (revised 6 January 2012)(1)

Candidate vaccine viruses

[Parent virus - Candidate vaccine virus - Type of virus or reassortant - Developing institute - Available from]

• A/Minnesota/11/2010
  • Wild type virus - CDC, USA
  • NYMC X-203 - Classical - New York Medical College, USA - NYMC, USA - CDC, USA
  • NYMC X-203A - Classical - New York Medical College, USA - NYMC, USA - CDC, USA

Institutes contact details for candidate vaccine viruses orders/information:

CDC: rdonis@cdc.gov
NYMC: doris_bucher@nymc.edu

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/en/



(1) Virus name changed following the joint FAO, OIE, WHO announcement of the standardization of terminology for the variant A(H3N2) virus recently infecting humans (http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/ )



-
-----